Treatment of hairy cell leukemia with recombinant α-interferon

J. R. Quesada, Evan M Hersh, J. Manning, J. Reuben, M. Keating, E. Schnipper, L. Itri, J. U. Gutterman

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Thirty patients with hairy cell leukemia were treated with recombinant interferon α-A (rIFN∅; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFNαA was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN∅ is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.

Original languageEnglish (US)
Pages (from-to)493-497
Number of pages5
JournalBlood
Volume68
Issue number2
StatePublished - 1986
Externally publishedYes

Fingerprint

Hairy Cell Leukemia
Interferons
Tumors
Cells
Blood
Biopsy
Bone
Therapeutics
Fatigue of materials
Splenomegaly
Incidence
Splenectomy
Tumor Burden
Fatigue
Neoplasms
Spleen
Bone Marrow
Quality of Life

ASJC Scopus subject areas

  • Hematology

Cite this

Quesada, J. R., Hersh, E. M., Manning, J., Reuben, J., Keating, M., Schnipper, E., ... Gutterman, J. U. (1986). Treatment of hairy cell leukemia with recombinant α-interferon. Blood, 68(2), 493-497.

Treatment of hairy cell leukemia with recombinant α-interferon. / Quesada, J. R.; Hersh, Evan M; Manning, J.; Reuben, J.; Keating, M.; Schnipper, E.; Itri, L.; Gutterman, J. U.

In: Blood, Vol. 68, No. 2, 1986, p. 493-497.

Research output: Contribution to journalArticle

Quesada, JR, Hersh, EM, Manning, J, Reuben, J, Keating, M, Schnipper, E, Itri, L & Gutterman, JU 1986, 'Treatment of hairy cell leukemia with recombinant α-interferon', Blood, vol. 68, no. 2, pp. 493-497.
Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E et al. Treatment of hairy cell leukemia with recombinant α-interferon. Blood. 1986;68(2):493-497.
Quesada, J. R. ; Hersh, Evan M ; Manning, J. ; Reuben, J. ; Keating, M. ; Schnipper, E. ; Itri, L. ; Gutterman, J. U. / Treatment of hairy cell leukemia with recombinant α-interferon. In: Blood. 1986 ; Vol. 68, No. 2. pp. 493-497.
@article{0ee63048d2dd4d0497fa6a5625a03ad7,
title = "Treatment of hairy cell leukemia with recombinant α-interferon",
abstract = "Thirty patients with hairy cell leukemia were treated with recombinant interferon α-A (rIFN∅; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFNαA was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN∅ is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.",
author = "Quesada, {J. R.} and Hersh, {Evan M} and J. Manning and J. Reuben and M. Keating and E. Schnipper and L. Itri and Gutterman, {J. U.}",
year = "1986",
language = "English (US)",
volume = "68",
pages = "493--497",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Treatment of hairy cell leukemia with recombinant α-interferon

AU - Quesada, J. R.

AU - Hersh, Evan M

AU - Manning, J.

AU - Reuben, J.

AU - Keating, M.

AU - Schnipper, E.

AU - Itri, L.

AU - Gutterman, J. U.

PY - 1986

Y1 - 1986

N2 - Thirty patients with hairy cell leukemia were treated with recombinant interferon α-A (rIFN∅; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFNαA was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN∅ is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.

AB - Thirty patients with hairy cell leukemia were treated with recombinant interferon α-A (rIFN∅; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFNαA was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN∅ is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.

UR - http://www.scopus.com/inward/record.url?scp=0022525650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022525650&partnerID=8YFLogxK

M3 - Article

C2 - 3730612

AN - SCOPUS:0022525650

VL - 68

SP - 493

EP - 497

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -